Case report: paraneoplastic cerebellar degeneration associated with anti-Yo antibody successfully treated with ofatumumab

• Published in: Frontiers in immunology Vol. 15; p. 1476397
• Main Authors: Dou, Jingjing, Yue, Xiaotong, Ren, Haitao, Wang, Chunjuan, Guo, Shougang
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 16.12.2024
• Subjects: anti-Yo antibody; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Autoantibodies - blood; Autoantibodies - immunology; CD20; CDR2; CDR2L; Female; Humans; Immunology; Middle Aged; Nerve Tissue Proteins - immunology; ofatumumab; paraneoplastic cerebellar degeneration; Paraneoplastic Cerebellar Degeneration - diagnosis; Paraneoplastic Cerebellar Degeneration - drug therapy; Paraneoplastic Cerebellar Degeneration - immunology; Treatment Outcome; CD20; anti-Yo antibody; CDR2L; ofatumumab; CDR2; paraneoplastic cerebellar degeneration

Paraneoplastic cerebellar degeneration (PCD) with anti-Yo antibodies represents a rare immune-mediated paraneoplastic neurological syndrome. Its diagnosis and management remain clinically challenging. Here, we present a case of PCD with confirmed anti-Yo antibodies, validated through anti-cerebellar...